← All trials
NCT04442048
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 25, 2020
- Primary completion
- Dec 31, 2020
- Completion date
- Mar 31, 2021
- First posted
- Jun 22, 2020
- Last posted
- Dec 16, 2020
- Enrollment
- 1500
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Canadian Cancer Trials GroupLead sponsor
- University of OttawaStudy chair
- Canadian Cancer SocietyCollaborator
- Ontario Institute for Cancer ResearchCollaborator
- Immodulon Therapeutics LtdCollaborator
- Canadian Cancer SocietyCollaborator
- NKMAX Co., Ltd.Collaborator
- BioCan RxCollaborator
- Canadian Centre for Applied Research in Cancer Control (ARCC)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.